3 Stocks With Realistic Paths to Double: ADMA Biologics, EyePoint Pharmaceuticals, and Viking Therapeutics
#SpaceX valuation#ADMA Biologics#EyePoint Pharmaceuticals#Viking Therapeutics#stocks with upside potential#biotech investing#growth stocks 2026#FDA approval pipeline#GLP-1 weight loss drugs#wet AMD treatment#immunoglobulin therapy#Wall Street analyst ratings
